Olokizumab + Omeprazole + Caffeine + Warfarin+ Vitamin K + Midazolam
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Rheumatoid Arthritis
Conditions
Rheumatoid Arthritis
Trial Timeline
Nov 16, 2021 → Oct 26, 2022
NCT ID
NCT04246762About Olokizumab + Omeprazole + Caffeine + Warfarin+ Vitamin K + Midazolam
Olokizumab + Omeprazole + Caffeine + Warfarin+ Vitamin K + Midazolam is a phase 1 stage product being developed by Thermo Fisher Scientific for Rheumatoid Arthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT04246762. Target conditions include Rheumatoid Arthritis.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04246762 | Phase 1 | Completed |
Competing Products
20 competing products in Rheumatoid Arthritis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Tilmanocept | Navidea Biopharmaceuticals | Phase 1 | 25 |
| Tc99m tilmanocept | Navidea Biopharmaceuticals | Phase 2 | 44 |
| KPL-404 + Placebo | Kiniksa Pharmaceuticals | Phase 2 | 47 |
| Baricitinib + Methotrexate + Baricitinib Placebo + MTX Placebo + Folic Acid | Eli Lilly | Phase 3 | 77 |
| LY2127399 | Eli Lilly | Phase 3 | 77 |
| Baricitinib + TNF Inhibitor | Eli Lilly | Approved | 85 |
| CT-P17 SC AI (adalimumab) | Celltrion | Phase 3 | 77 |
| Remsima IV + Remsima SC | Celltrion | Pre-clinical | 23 |
| CT-P13 + Remicade | Celltrion | Phase 3 | 77 |
| CT-P47 + EU-approved RoActemra | Celltrion | Phase 3 | 77 |
| Infliximab | Celltrion | Phase 3 | 77 |
| CT-P13 SC Auto-Injector + Placebo Auto-Injector | Celltrion | Phase 3 | 77 |
| Rituximab, MTX, folic acid | Celltrion | Phase 1 | 33 |
| CT-P10 + Rituxan + MabThera | Celltrion | Phase 3 | 77 |
| CT-P47 AI (tocilizumab) + CT-P47 PFS (tocilizumab) | Celltrion | Phase 3 | 77 |
| CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13 | Celltrion | Phase 3 | 77 |
| rituximab | Celltrion | Phase 1 | 33 |
| CT-P17 SC + Humira SC | Celltrion | Phase 3 | 77 |
| Adalimumab | Celltrion | Pre-clinical | 23 |
| Infliximab | Celltrion | Phase 3 | 77 |
Other Products from Thermo Fisher Scientific
Tolvaptan + placeboPhase 3
76
zamtocabtagene autoleucel (MB-CART2019.1)Phase 2
51
BGP-15 100 mg QD + BGP-15 100 mg BID + Placebo BID + BGP-15 200 mg QD + BGP-15 200 mg BID + BGP-15 400 mg QDPhase 2
51
LR-ESHAP (lenalidomide 5 mg) + LR-ESHAP (lenalidomide 10 mg) + LR-ESHAP (lenalidomide 15 mg) + LR-ESHAP (lenalidomide 20 mg)Phase 1/2
40
ShA9 Topical Gel + Hydrocortisone Ointment + Clobetasol Ointment + Fluocinonide Ointment + Placebo (Vehicle) Topical GelPhase 1
32